Metabotropic glutamate receptor 5 binding and protein expression in schizophrenia and following antipsychotic drug treatment

Schizophrenia Research

Volumn 146, Issue 1-3, 2013, Pages 170-176

  Matosin, Natalie ^a,b   Frank, Elisabeth ^a,b   Deng, Chao ^a,b   Huang, Xu Feng ^a,b   Newell, Kelly A ^a,b  

^a UNIVERSITY OF WOLLONGONG   (Australia)

^b Schizophrenia Research Institute (SRI)   (Australia)

Author keywords

Antipsychotic; Dorsolateral prefrontal cortex; MGluR5; Post mortem human brain tissue; Schizophrenia

Indexed keywords

HALOPERIDOL; METABOTROPIC RECEPTOR 5; NEUROLEPTIC AGENT; OLANZAPINE;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING SITE; BRAIN CORTEX; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DRUG EFFECT; FEMALE; HIPPOCAMPUS; HUMAN; HUMAN TISSUE; LONG TERM CARE; MALE; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; RAT; SCHIZOPHRENIA; SHORT COURSE THERAPY; THALAMUS;

ADOLESCENT; ADULT; AGED; ANALYSIS OF VARIANCE; ANIMALS; ANTIPSYCHOTIC AGENTS; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; FUNCTIONAL LATERALITY; HUMANS; MALE; MIDDLE AGED; POSTMORTEM CHANGES; PROTEIN BINDING; PYRIDINES; RADIOLIGAND ASSAY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, METABOTROPIC GLUTAMATE; SCHIZOPHRENIA; TIME FACTORS; TRITIUM; YOUNG ADULT;

EID: 84875942805     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2013.01.018     Document Type: Article

References (44)

1. Agnati L.F., Guidolin D., Albertin G., Trivello E., Ciruela F., Genedani S., Tarakanov A., Fuxe K. An integrated view on the role of receptor mosaics at perisynaptic level: focus on adenosine A2A, dopamine D2, cannabinoid CB1, and metabotropic glutamate mGlu5 receptors. J. Recept. Signal Transduct. 2010, 30(5):355-369.
2. Alagarsamy S., Rouse S.T., Junge C., Hubert G., Gutman D., Smith Y., Conn P.J. NMDA-induced phosphorylation and regulation of mGluR5. Pharmacol. Biochem. Behav. 2002, 73(2):299-306.
3. Alagarsamy S., Saugstad J., Warren L., Mansuy I.M., Gereau R.W., Conn P.J. NMDA-induced potentiation of mGluR5 is mediated by activation of protein phosphatase 2B/calcineurin. Neuropharmacology 2005, 49:135-145. (Supplement).
4. Benquet P., Gee C.E., Gerber U. Two distinct signaling pathways upregulate NMDA receptor responses via two distinct metabotropic glutamate receptor subtypes. J. Neurosci. 2002, 22(22):9679-9686.
5. Brody S., Dulawa S., Conquet F., Geyer M. Assessment of a prepulse inhibition deficit in a mutant mouse lacking mGlu5 receptors. Mol. Psychiatry 2004, 9(1):35-41.
6. Chen Y., Nong Y., Goudet C., Hemstapat K., De Paulis T., Pin J.P., Conn P.J. Interaction of novel positive allosteric modulators of metabotropic glutamate receptor 5 with the negative allosteric antagonist site is required for potentiation of receptor responses. Mol. Pharmacol. 2007, 71(5):1389-1398.
7. Corti C., Xuereb J.H., Crepaldi L., Corsi M., Michielin F., Ferraguti F. Altered levels of glutamatergic receptors and Na+/K+ ATPase-α1 in the prefrontal cortex of subjects with schizophrenia. Schizophr. Res. 2011, 128(1-3):7-14.
8. Crook J., Akil M., Law B., Hyde T., Kleinman J. Comparative analysis of group II metabotropic glutamate receptor immunoreactivity in Brodmann's area 46 of the dorsolateral prefrontal cortex from patients with schizophrenia and normal subjects. Mol. Psychiatry 2002, 7(2):157-164.
9. Deakin J., Slater P., Simpson M., Gilchrist A., Skan W., Royston M., Reynolds G., Cross A. Frontal cortical and left temporal glutamatergic dysfunction in schizophrenia. J. Neurochem. 1989, 52(6):1781-1786.
10. Deschwanden A., Karolewicz B., Feyissa A.M., Treyer V., Ametamey S.M., Johayem A., Burger C., Auberson Y.P., Sovago J., Stockmeier C.A. Reduced metabotropic glutamate receptor 5 density in major depression determined by [11C] ABP688 PET and postmortem study. Am. J. Psychiatry 2011, 168(7):727.
11. Eisenberg D.P., Berman K.F. Executive function, neural circuitry, and genetic mechanisms in schizophrenia. Neuropsychopharmacology 2010, 35(1):258-277.
12. Ellenbroek B.A. Psychopharmacological treatment of schizophrenia: what do we have, and what could we get?. Neuropharmacology 2012, 62(3):1371-1380.
13. Frank E., Newell K.A., Huang X.F. Density of metabotropic glutamate receptors 2 and 3 (mGluR2/3) in the dorsolateral prefrontal cortex does not differ with schizophrenia diagnosis but decreases with age. Schizophr. Res. 2011, 128(1-3):56-60.
14. Fung S.J., Webster M.J., Sivagnanasundaram S., Duncan C., Elashoff M., Weickert C.S. Expression of interneuron markers in the dorsolateral prefrontal cortex of the developing human and in schizophrenia. Am. J. Psychiatry 2010, 167(12):1479-1488.
15. Greenbaum D., Colangelo C., Williams K., Gerstein M. Comparing protein abundance and mRNA expression levels on a genomic scale. Genome Biol. 2003, 4(9):117.
16. Gupta D.S., McCullumsmith R.E., Beneyto M., Haroutunian V., Davis K.L., Meador Woodruff J.H. Metabotropic glutamate receptor protein expression in the prefrontal cortex and striatum in schizophrenia. Synapse 2005, 57(3):123-131.
17. Han M., Newell K.A., Zavitsanou K., Deng C., Huang X.F. Effects of antipsychotic medication on muscarinic M1 receptor mRNA expression in the rat brain. J. Neurosci. Res. 2008, 86(2):457-464.
18. Homayoun H., Moghaddam B. Bursting of prefrontal cortex neurons in awake rats is regulated by metabotropic glutamate 5 (mGlu5) receptors: rate-dependent influence and interaction with NMDA receptors. Cereb. Cortex 2006, 16(1):93.
19. Homayoun H., Moghaddam B. Orbitofrontal cortex neurons as a common target for classic and glutamatergic antipsychotic drugs. Proc. Natl. Acad. Sci. U. S. A. 2008, 105(46):18041-18046.
20. Homayoun H., Stefani M.R., Adams B.W., Tamagan G.D., Moghaddam B. Functional interaction between NMDA and mGlu5 receptors: effects on working memory, instrumental learning, motor behaviors, and dopamine release. Neuropsychopharmacology 2004, 29(7):1259-1269.
21. Hynd M.R., Lewohl J.M., Scott H.L., Dodd P.R. Biochemical and molecular studies using human autopsy brain tissue. J. Neurochem. 2003, 85(3):543-562.
22. Iasevoli F., Fiore G., Cicale M., Muscettola G., de Bartolomeis A. Haloperidol induces higher Homer1a expression than risperidone, olanzapine and sulpiride in striatal sub-regions. Psychiat. Res. 2010, 177:255-260.
23. Kantrowitz J.T., Javitt D.C. N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: the final common pathway on the road to schizophrenia?. Brain Res. Bull. 2010, 83(3-4):108-121.
24. Kinney G.G., Burno M., Campbell U.C., Hernandez L.M., Rodriguez D., Bristow L.J., Conn P.J. Metabotropic glutamate subtype 5 receptors modulate locomotor activity and sensorimotor gating in rodents. J. Pharmacol. Exp. Ther. 2003, 306(1):116-123.
25. Koros E., Rosenbrock H., Birk G., Weiss C., Sams-Dodd F. The selective mGlu5 receptor antagonist MTEP, similar to NMDA receptor antagonists, induces social isolation in rats. Neuropsychopharmacology 2006, 32(3):562-576.
26. Krivoy A., Fischel T., Weizman A. The possible involvement of metabotropic glutamate receptors in schizophrenia. European Neuropsychopharmacol. Eur. Neuropsychopharmacol. 2008, 18(6):395.
27. Luccini E., Musante V., Neri E., Brambilla Bas M., Severi P., Raiteri M., Pittaluga A. Functional interactions between presynaptic NMDA receptors and metabotropic glutamate receptors co expressed on rat and human noradrenergic terminals. Br. J. Pharmacol. 2007, 151(7):1087-1094.
28. Marek G.J., Behl B., Bespalov A.Y., Gross G., Lee Y., Schoemaker H. Glutamatergic (N-methyl-d-aspartate receptor) hypofrontality in schizophrenia: too little juice or a miswired brain?. Mol. Pharmacol. 2010, 77(3):317.
29. Matosin N., Newell K.A. Metabotropic glutamate receptor 5 in the pathology and treatment of schizophrenia. Neurosci. Biobehav. Rev. 2013, 37(3):256-268.
30. Niswender C.M., Conn P.J. Metabotropic glutamate receptors: physiology, pharmacology, and disease. Annu. Rev. Pharmacol. Toxicol. 2010, 50:295-322.
31. Ohnuma T., Augood S.J., Arai H., McKenna P.J., Emson P.C. Expression of the human excitatory amino acid transporter 2 and metabotropic glutamate receptors 3 and 5 in the prefrontal cortex from normal individuals and patients with schizophrenia. Mol. Brain Res. 1998, 56(1-2):207-217.
32. Ohnuma T., Tessler S., Arai H., Faull R.L.M., McKenna P.J., Emson P.C. Gene expression of metabotropic glutamate receptor 5 and excitatory amino acid transporter 2 in the schizophrenic hippocampus. Mol. Brain Res. 2000, 85(1-2):24-31.
33. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates 2007, Academic Press, Australia. Sixth ed.
34. Perlstein W.M., Carter C.S., Noll D.C., Cohen J.D. Relation of prefrontal cortex dysfunction to working memory and symptoms in schizophrenia. Am. J. Psychiatry 2001, 158(7):1105-1113.
35. Pisani A., Gubellini P., Bonsi P., Conquet F., Picconi B., Centonze D., Bernardi G., Calabresi P. Metabotropic glutamate receptor 5 mediates the potentiation of N-methyl-aspartate responses in medium spiny striatal neurons. Neuroscience 2001, 106(3):579-587.
36. Richardson-Burns S.M., Haroutunian V., Davis K.L., Watson S.J., Meador-Woodruff J.H. Metabotropic glutamate receptor mRNA expression in the schizophrenic thalamus. Biol. Psychiatry 2000, 47(1):22-28.
37. Samadi P., Grègoire L., Morissette M., Calon F., Hadj Tahar A., Dridi M., Belanger N., Meltzer L.T., Bèdard P.J., Di Paolo T. mGluR5 metabotropic glutamate receptors and dyskinesias in MPTP monkeys. Neurobiol. Aging 2008, 29(7):1040-1051.
38. Tu J.C., Xiao B., Naisbitt S., Yuan J.P., Petralia R.S., Brakeman P., Doan A., Aakalu V.K., Lanahan A.A., Sheng M. Coupling of mGluR/Homer and PSD-95 complexes by the Shank family of postsynaptic density proteins. Neuron 1999, 23(3):583-592.
39. Vinson P., Conn J.P. Metabotropic glutamate receptors as therapeutic targets for schizophrenia. Neuropharmacology 2012, 62(3):1461-1472.
40. Volk D.W., Eggan S.M., Lewis D.A. Alterations in metabotropic glutamate receptor 1a and regulator of G protein signaling 4 in the prefrontal cortex in schizophrenia. Am. J. Psychiatry 2010, 167(12):1489-1498.
41. Weickert C.S., Sheedy D., Rothmond D.A., Dedova I., Fung S., Garrick T., Wong J., Harding A.J., Sivagnanansundaram S., Hunt C. Selection of reference gene expression in a schizophrenia brain cohort. Aust. N. Z. J. Psychiatry 2010, 44(1):59-70.
42. Weickert, C.S., Fung, S.J., Catts, V.S., Schofield, P.R., Allen, K.M., Moore, L.T., Newell, K.A., Pellen, D., Huang, X-F., Catts, S.V., Weickert, T.W. in press. Molecular evidence of N-methyl-D-aspartate receptor hypofunction in schizophrenia. Mol. Psychiatry. http://dx.doi.org/10.1038/mp.2012.137.
43. Weston-Green K., Huang X.F., Lian J., Deng C. Effects of olanzapine on muscarinic M3 receptor binding density in the brain relates to weight gain, plasma insulin and metabolic hormone levels. Eur. Neuropsychopharmacol. 2012, 22:364-373.
44. Yang Y., Fung S.J., Rothwell A., Tianmei S., Weickert C.S. Increased interstitial white matter neuron density in the dorsolateral prefrontal cortex of people with schizophrenia. Biol. Psychiatry 2010, 69(1):63-70.